Genenta Science (NASDAQ:GNTA) Trading Down 1.3% – Here’s What Happened

Shares of Genenta Science S.p.A. (NASDAQ:GNTA) dropped 1.3% during mid-day trading on Friday . The company traded as low as $3.51 and last traded at $3.76. Approximately 22,483 shares changed hands during trading, an increase of 43% from the average daily volume of 15,753 shares. The stock had previously closed at $3.81.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Stock Performance

The business has a 50-day moving average of $4.88 and a two-hundred day moving average of $4.56.

Institutional Trading of Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. purchased a new stake in Genenta Science S.p.A. (NASDAQ:GNTA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science at the end of the most recent reporting period. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.